Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    - Revision updated from v3.4.2 to v3.4.3; no user-visible changes to the study page.
    Difference
    0.0%
    Check dated 2026-03-12T21:00:05.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    A minor page revision was applied, moving from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-12T01:41:51.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Only a page revision update from v3.4.0 to v3.4.1 is visible; no core content or study data changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-04T23:06:54.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    UI and metadata elements were updated, including a visible 'Show glossary' label and capitalization adjustments to the QC-related update text. A site revision banner now shows v3.4.0, replacing the previous v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-28T21:32:51.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no substantive changes to study data, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:53:40.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The page's Locations section has been expanded to include new sites across the United States and international locations such as Australia and European regions. This broadens the list of enrolling centers and may affect where patients can participate.
    Difference
    2%
    Check dated 2025-12-23T21:32:33.000Z thumbnail image

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.